Combining epitope-distinct antibodies to HER2: Cooperative inhibitory effects on invasive growth

Oncogene

Volumn 30, Issue 14, 2011, Pages 1631-1642

  Emde, A ^a   Pradeep, C R ^a   Ferraro, D A ^a   Ben Chetrit, N ^a   Sela, M ^a   Ribba, B ^b   Kam, Z ^a   Yarden, Y ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

3D culture; breast cancer; growth factor; trastuzumab; tyrosine kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GROWTH FACTOR; LAPATINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 431; MONOCLONAL ANTIBODY N12; NEUREGULIN BETA 1; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CELL; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; DRUG POTENTIATION; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPHEROID CELL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; EPITOPES; FEMALE; HUMANS; MONOCYTE CHEMOATTRACTANT PROTEINS; RECEPTOR, ERBB-2;

EID: 79953782986     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.547     Document Type: Article

References (38)

1. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI et al. (2002). Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127-137. (Pubitemid 41039113)
2. Aranda V, Haire T, Nolan ME, Calarco JP, Rosenberg AZ, Fawcett JP et al. (2006). Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat Cell Biol 8: 1235-1245. (Pubitemid 44660588)
3. Baselga J. (2006). Targeting tyrosine kinases in cancer: the second wave. Science 312: 1175-1178. (Pubitemid 43801135)
4. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J et al. (2009). Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27: 2630-2637.
5. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. (2009). Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci USA 106: 3294-3299.
6. Ben-Kasus T, Schechter B, Sela M, Yarden Y. (2007). Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol Oncol 1: 42-54. (Pubitemid 46776618)
7. Citri A, Yarden Y. (2006). EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516. (Pubitemid 44036456)
8. Clynes RA, Towers TL, Presta LG, Ravetch JV. (2000). Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446. (Pubitemid 30208162)
9. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS. (2002). The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111: 29-40.
10. Drebin JA, Link VC, Greene MI. (1988). Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2: 273-277. (Pubitemid 18085307)
11. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS et al. (2005). Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci USA 102: 1915-1920. (Pubitemid 40261987)
12. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G et al. (2006). Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 126: 489-502. (Pubitemid 44163602)
13. Hou L, Shi D, Tu SM, Zhang HZ, Hung MC, Ling D. (1992). Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett 65: 215-220.
14. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D et al. (2008). Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 13: 394-406. (Pubitemid 351609443)
15. Hynes NE, MacDonald G. (2009). ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21: 177-184.
16. Kasprzyk PG, Song SU, Di Fiore PP, King CR. (1992). Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 52: 2771-2776.
17. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M. (1997). A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14: 2099-2109. (Pubitemid 27237013)
18. Lemieux J, Clemons M, Provencher L, Dent S, Latreille J, Mackey J et al. (2009). The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers. Curr Oncol 16: 48-57.
19. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS. (2001). ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 3: 785-792. (Pubitemid 32842683)
20. Nahta R, Esteva FJ. (2006). Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123-138. (Pubitemid 43170962)
21. Nahta R, Hung MC, Esteva FJ. (2004). The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64: 2343-2346. (Pubitemid 38523885)
22. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS et al. (2010). Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 70: 588-597.
23. Pickl M, Ries CH. (2009). Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 28: 461-468.
24. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA et al. (2007). Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919. (Pubitemid 47294799)
25. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. (2009). Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69: 9330-9336.
26. Schneider PM, Hung MC, Chiocca SM, Manning J, Zhao XY, Fang K et al. (1989). Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49: 4968-4971. (Pubitemid 19239327)
27. Seton-Rogers SE, Brugge JS. (2004). ErbB2 and TGF-beta: a cooperative role in mammary tumor progression? Cell Cycle 3: 597-600. (Pubitemid 40278199)
28. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182. (Pubitemid 17231334)
29. Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA et al. (2010). Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci USA 107: 13252-13257.
30. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL et al. (2002). Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8: 1720-1730. (Pubitemid 34633727)
31. Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL. (2004). Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem 279: 24505-24513. (Pubitemid 38725316)
32. Weiner DB, Nordberg J, Robinson R, Nowell PC, Gazdar A, Greene MI et al. (1990). Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 50: 421-425. (Pubitemid 20041252)
33. Xia W, Lau YK, Zhang HZ, Liu AR, Li L, Kiyokawa N et al. (1997). Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 3: 3-9. (Pubitemid 27079437)
34. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW et al. (2002). Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21: 6255-6263.
35. Yarden Y, Sliwkowski MX. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137. (Pubitemid 33674041)
36. Yip YL, Smith G, Koch J, Dubel S, Ward RL. (2001). Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J Immunol 166: 5271-5278. (Pubitemid 32280745)
37. Yoshida K, Tsuda T, Matsumura T, Tsujino T, Hattori T, Ito H et al. (1989). Amplification of epidermal growth factor receptor (EGFR) gene and oncogenes in human gastric carcinomas. Virchows Arch B 57: 285-290. (Pubitemid 19204055)
38. Zhan L, Xiang B, Muthuswamy SK. (2006). Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors. Cancer Res 66: 5201-5208. (Pubitemid 43844943)